



City Research Online

City, University of London Institutional Repository

Citation: Mizuno, S., Iwami, M., Kunisawa, S., Naylor, N., Yamashita, K., Kyratsis, Y., Meads, G., Otter, J., Holmes, A. & Ahmad, R. (2018). Comparison of national strategies to reduce methicillin-resistant *Staphylococcus aureus* (MRSA) infections in Japan and England. *Journal of Hospital Infection*, 100(3), pp. 280-298. doi: 10.1016/j.jhin.2018.06.026

This is the accepted version of the paper.

This version of the publication may differ from the final published version.

Permanent repository link: <https://openaccess.city.ac.uk/id/eprint/20177/>

Link to published version: <https://doi.org/10.1016/j.jhin.2018.06.026>

Copyright: City Research Online aims to make research outputs of City, University of London available to a wider audience. Copyright and Moral Rights remain with the author(s) and/or copyright holders. URLs from City Research Online may be freely distributed and linked to.

Reuse: Copies of full items can be used for personal research or study, educational, or not-for-profit purposes without prior permission or charge. Provided that the authors, title and full bibliographic details are credited, a hyperlink and/or URL is given for the original metadata page and the content is not changed in any way.

City Research Online:

<http://openaccess.city.ac.uk/>

publications@city.ac.uk

Accepted Manuscript

Comparison of national strategies to reduce methicillin-resistant *Staphylococcus aureus* (MRSA) infections in Japan and England

Seiko Mizuno, Michiyo Iwami, Susumu Kunisawa, Nichola Naylor, Kazuto Yamashita, Yiannis Kyratsis, Geoffrey Meads, Jonathan A. Otter, Alison Holmes, Yuichi Imanaka, Raheelah Ahmad

PII: S0195-6701(18)30363-3

DOI: [10.1016/j.jhin.2018.06.026](https://doi.org/10.1016/j.jhin.2018.06.026)

Reference: YJHIN 5477


To appear in: *Journal of Hospital Infection*

Received Date: 30 April 2018

Accepted Date: 28 June 2018

Please cite this article as: Mizuno S, Iwami M, Kunisawa S, Naylor N, Yamashita K, Kyratsis Y, Meads G, Otter JA, Holmes A, Imanaka Y, Ahmad R, Comparison of national strategies to reduce methicillin-resistant *Staphylococcus aureus* (MRSA) infections in Japan and England, *Journal of Hospital Infection* (2018), doi: 10.1016/j.jhin.2018.06.026.

This is a PDF file of an unedited manuscript that has been accepted for publication. As a service to our customers we are providing this early version of the manuscript. The manuscript will undergo copyediting, typesetting, and review of the resulting proof before it is published in its final form. Please note that during the production process errors may be discovered which could affect the content, and all legal disclaimers that apply to the journal pertain.



1 **Title:** Comparison of national strategies to reduce methicillin-resistant *Staphylococcus aureus* (MRSA)
2 infections in Japan and England

3
4 Seiko Mizuno^{a*}, Michiyo Iwami^{b*}, Susumu Kunisawa^a, Nichola Naylor^c, Kazuto Yamashita^a, Yiannis
5 Kyratsis^d, Geoffrey Meads^e, Jonathan A. Otter^{c,f}, Alison Holmes^{c,f}, Yuichi Imanaka^a, Raheelah
6 Ahmad^{c,g**}

7
8 **Author affiliations:**

9 ^a Department of Healthcare Economics and Quality Management, Kyoto University, Japan.

10 ^b Division of Infectious Diseases, Imperial College London.

11 ^c NIHR Health Protection Research Unit in Healthcare Associated Infection and Antimicrobial
12 Resistance, Imperial College London, Hammersmith Campus, du Cane Road, London, United Kingdom
13 W12 0NN.

14 ^d Health Services Research & Management Division, School of Health Sciences, City University of
15 London, United Kingdom.

16 ^e Health and Wellbeing Research Group, University of Winchester, United Kingdom.

17 ^f Imperial College Healthcare NHS Trust, Hammersmith Hospital, du Cane Road, London, United
18 Kingdom W12 0HS.

19 ^g Health Group, Management Department, Imperial College Business School, Exhibition Road,
20 London, United Kingdom.

21
22 *Contributed equally.

23 ****Corresponding author:** Dr Raheelah Ahmad

24 Address: NIHR Health Protection Research Unit in Healthcare Associated Infection and Antimicrobial
25 Resistance, Imperial College London, Hammersmith Campus, du Cane Road, London, United Kingdom
26 W12 0NN

27 Tel: +44 (0)20 3313 3244

28 Email: raheelah.ahmad@imperial.ac.uk

29 **Running title:** MRSA strategies in Japan and England

1 **Structured summary**

2 *Background:* National responses to healthcare-associated infections vary between high-income
3 countries but when analysed for contextual comparability, interventions can be assessed for
4 transferability.

5 *Aim:* To identify learning from country-level approaches to addressing meticillin-resistant
6 *Staphylococcus aureus* (MRSA) in Japan and England.

7 *Methods:* A longitudinal analysis (2000-17), comparing epidemiological trends and policy
8 interventions. Data from 441 textual sources concerning infection prevention and control (IPC),
9 surveillance, and antimicrobial stewardship interventions were systematically coded for: *type* -
10 mandatory requirements, recommendations, or national campaigns; *method* - restrictive, persuasive,
11 structural in nature; *level of implementation* - macro (national), meso (organisational), micro
12 (individual) levels. Healthcare organisational structures and role of media were also assessed.

13 *Findings:* In England significant reduction has been achieved in number of reported MRSA
14 bloodstream infections. In Japan, in spite of reductions, MRSA remains a predominant infection.
15 Both countries face new threats in the emergence of drug-resistant *Escherichia coli*. England has
16 focused on national mandatory and structural interventions, supported by a combination of
17 outcomes-based incentives and punitive mechanisms, and multidisciplinary IPC hospital teams.
18 Japan has focused on (non-mandatory) recommendations and primarily persuasive interventions,
19 supported by process-based incentives, with voluntary surveillance. Areas for development in Japan
20 include resourcing of dedicated data management support and implementation of national
21 campaigns for healthcare professionals and the public.

22 *Conclusion:* Policy interventions need to be relevant to local epidemiological trends, while
23 acceptable within health system cultures and public expectations. Cross-national learning can help
24 inform the right mix of interventions to create sustainable and resilient systems for future infection
25 and economic challenges.

26

27 **Keywords**

28 Meticillin-resistant *Staphylococcus aureus*; antimicrobial resistance; infection prevention and control;
29 healthcare-associated infections

30 **Introduction**

31 Antimicrobial resistance (AMR) and healthcare-associated infections (HCAIs) remain a critical global
32 challenge[1]. While a standard template for National Action Plans for AMR has been suggested,
33 countries have adopted different interventions to address AMR and HCAIs. A better understanding of
34 what has been attempted at the national level can offer improved contextualisation for the often
35 challenging implementation of large-scale interventions such as National Action Plans. By comparing
36 international responses across different countries, a look at the wider policy setting can help
37 transfer of learning. Global transfer of learning has influenced UK initiatives in the past (e.g. primary
38 care organisational development [2]) but for infection prevention and control (IPC), England has
39 deviated from its European neighbours in policy approach and particularly the amount of
40 information available in the public domain [3]. International collaboration and cross-border learning
41 from innovative models tackling AMR are encouraged by the UK Department of Health (DH)[4] and
42 Japan Ministry of Health Labour and Welfare (MHLW)[5]. High-income countries, such as Japan and
43 UK, face a further challenge arising from ageing populations, which require careful consideration of
44 sustainable approaches.

45 The AMR National Action Plans in both countries cover similar overarching themes. The Japanese
46 government formulated its plan in April 2016, aiming to cut total antibiotic usage by 33% of the
47 current level by 2020 [5]. However, the UK, in its Five Year AMR Strategy (2013-2018), has
48 approached the setting of AMR targets differently [4]. The UK is implementing continuous yearly
49 review and revised targets using baselines, starting with ten different drug-bug combinations [4].
50 MRSA is not included because of the earlier focus and achievement [6], [7]. Japan has implemented a
51 reduction programme with a set target for achievement by 2020 for each one of six different drug-
52 resistant bacteria, including MRSA [5].

53 This study addressed the question: What can be learnt from approaches for addressing MRSA
54 between two high-income countries?

55

56 **Methods**

57 This study involved the collection and analysis of secondary data to systematically map and
58 understand the trajectory of national-level interventions to address MRSA as follows.

59 *(i)* Observing the epidemiological setting

60 The most complete datasets (chronologically) in each country were accessed, data extracted and
61 trends plotted (on MS Excel). For England, the publicly accessible Public Health England (formerly
62 Health Protection Agency) data were used [8]–[12]. We included four infections for which NHS acute
63 hospital trusts have been subject to mandatory surveillance and public reporting in England:
64 methicillin-resistant *Staphylococcus aureus* (MRSA), methicillin-sensitive *S. aureus* (MSSA), and *E. coli*
65 bloodstream infections (BSIs), and *Clostridium difficile* infection. The financial year 2001/2 was the
66 start point of the analysis in line with initiation of mandatory surveillance, and public reporting of
67 MRSA. Other Gram-negative organisms, *Pseudomonas aeruginosa* and *Klebsiella* species, which
68 became subject to mandatory surveillance and public reporting only in 2017, were not included in
69 this study.

70 In Japan, since 1999 MRSA infections have been the subject of sentinel surveillance with 500
71 designated hospitals required to report their monthly number of patients with MRSA infection [13].
72 This covers approximately 6% of 8000 hospitals in Japan. In 2000, The Japan Nosocomial Infections
73 Surveillance (JANIS), organised by the MHLW, was launched to collect data on multidrug-resistant
74 organism (MDRO) nosocomial infections such as MRSA on a voluntary basis. JANIS member hospitals
75 are required to submit surveillance data monthly. The JANIS system provides anonymous ‘Open
76 Reports’ for the public (quarterly & annually) and ‘Feedback Reports’ for member hospitals (monthly
77 & annually). Data from the divisions of Antimicrobial-Resistant Bacterial Infection (ARBI) and Clinical
78 Laboratory (CL) at JANIS were accessed [14]. These data represent 10% and 19.5% of hospitals (2016)
79 respectively [15]. The CL division reports prevalence of bacteria amongst clinical isolates based on
80 microbiological data [14]. Whilst ARBI data have less coverage, they are used here as capture the
81 incidence of seven different (multi)drug-resistant infections associated with six bacteria, including
82 MRSA, amongst hospitalised patients. The ARBI data are more comparable with England data on
83 MRSA BSI rather than the CL data. The CL data are included as supplementary data (Appendix A,
84 **Figure A.1**) as include additional pathogens. Pre-2007 data for Japan were excluded, as longitudinal
85 comparison is inappropriate due to different data collection systems. Across the countries, there is a
86 difference in the denominators for epidemiological data due to different data collection methods.

87

88 (ii) Assessment of the health policy setting

89 To map policy interventions for the period 2000-17, we purposefully sampled secondary data
90 sources, concerning wider IPC, surveillance, antimicrobial stewardship as key areas to address AMR,
91 including MRSA [16]. The start point of 2000 is used for both countries to align with publication of
92 two key reports by the US Institute of Medicine [17], [18] pointing out prevalence of hospital

93 infections, harnessing national commitment to patient safety, followed by country actions globally.
94 As a first study to provide a rapid, efficient, but in-depth comparison of approaches post-2000,
95 between Japan and England, a decision to use secondary sources was taken; setting the ground for
96 future interviews and surveys.

97 The sampling was informed by field experts, such as senior clinicians and policy makers in each
98 country. For Japan, a total of 275 textual sources were analysed from four main categories: (a) policy
99 documents, guidelines, and legislation produced by Japan's health bodies; (b) hospital human
100 resource documents, board minutes, reports and strategies on IPC (for a sample of five hospitals in
101 Japan); (c) documentary evidence from professional associations; (d) documentary material from
102 outside healthcare, such as newspaper articles concerning HCAs and AMR. For England, we
103 supplemented archival data of previous research conducted by the research team [6], [19], which
104 resulted in 322 textual sources being retrieved and analysed for (a)-(c). We did not conduct analysis
105 for media materials for England in this study, as this has been captured elsewhere in recent years
106 [20], [21] with a frequency of reporting 'AMR'/'antibiotic resistance' and 'superbug' in the media
107 averaging at up to 4.7 per month in popular and broadsheet newspapers between 2010-15 [22].

108

109 Using keyword searches taking into account relevant key literature [7], [23]–[26], an inventory of
110 interventions was compiled. This inventory was then refined through an iterative process, including a
111 series of team virtual discussions and emails about its appropriateness. Data from 441 textual
112 sources were then independently and systematically mapped and coded along three dimensions: a.
113 type - mandatory requirements, recommendations, or national campaigns; b. method – restrictive,
114 persuasive, and/or structural in nature [27], [28]; c. level of implementation - macro (national), meso
115 (organisational), and/or micro (individual) levels. This was done independently and concurrently
116 between the research teams. A further 156 materials were also analysed for role of media (for Japan)
117 and healthcare organisational structures.

118 Examples for restrictive interventions include limits or required approvals, such as formulary
119 restriction requiring prior authorisation of prescriptions by infectious diseases physicians. Persuasive
120 interventions refer to education, training, local consensus processes, advice, audit and feedback.
121 Structural interventions include shifting towards electronic records, provision of rapid laboratory
122 testing and technology, and organisation of quality monitoring mechanisms. Two researchers
123 independently coded all data for each country (SM - Japan, MI- England). A second, independent
124 coding was carried out for Japan for 30% of the interventions (MI bilingual). A second, independent

125 coding was carried out for England for 30% of the interventions (RA & YK). A third level of
126 independent coding was carried out for discrepancies arising (RA). Disagreements in the results were
127 resolved through team (virtual) discussions (SM, SK, MI, RA).

128

129 *(iii) Wider contextual analysis*

130 For a broader contextualisation of policy interventions we gathered information based on a classic
131 policy appraisal framework, namely *Leichter's*: (i) situational factors (i.e. change of government and
132 national leadership, health, healthcare utilisation); (ii) structural factors (i.e. socio-economic
133 indicators, health expenditures, health workforce, population); (iii) cultural factors (i.e. cultural
134 values); and (iv) exogenous factors (i.e. influence of international institutions) [29].

135 The approaches above allowed a multi-dimensional comparison of approaches over time between
136 Japan and England.

137

138 **Results**

139 *(i) The Epidemiological Setting*

140 MRSA remains highly prevalent in Japanese hospitals. Although MRSA infections have been
141 decreasing over the last decade, the speed of decline appears to have slowed down after 2013, with
142 2016 rates at 311 per 100 000 hospitalized patients [15]. The trend of other (multi)drug-resistant
143 bacterial infections based on ARBI data either showed a decline or did not change during the
144 observed period (2007-2016) (**Figure 1**). CL data show *E. coli* and drug-resistant *E. coli*
145 (cephalosporin, fluoroquinolone) isolates have rapidly increased in recent years, reaching similar
146 levels to *S. aureus* isolates (Appendix A, **Figure A.1**).

147 In England, there was a sharp drop in the rates of MRSA BSIs between 2006/7 and 2009/10, and then
148 the speed of decline slowed down between 2009/10 and 2011/12. MRSA levels have plateaued since
149 2011/12 with all reported cases per 100 000 bed days below 5. Not all trends are in the right
150 direction despite being subject to mandatory surveillance since 2001 (later implementation for *E.*
151 *coli*, MSSA – 2011/12) (**Figure 2**). *E. coli* represents a rapid increase and the most frequent cause of
152 BSIs; 41% of these were resistant to co-amoxiclav (commonest antibiotic used in hospitals) in 2016
153 [30].

154 Regional variation is also reported between Europe and Asia as well as England and Japan. *S. aureus*'s
155 resistance to methicillin was reported as 6.7% (invasive isolates, 2016) in the UK, 13.7% in EU/EEA
156 [31], whereas Japan and Asian Network for Surveillance of Resistant Pathogens accounted for 53%
157 (comprehensive, 2012) and 64% (blood isolates, 2012) respectively [32].

158 *(ii) The Health Policy Setting*

159 Since 1996, the Japanese government has promoted infection control in hospitals using a medical
160 reimbursement system. Hospitals which have in place methods for developing staff and capacity
161 building as well as taking part in surveillance, establishment of a hospital infection control
162 department/committee, and associated activities, are eligible to apply for an additional fee through
163 reimbursement systems. Those hospitals that do not have systems to monitor optimal use of
164 antimicrobials are barred from applying for this fee. A key feature of monitoring must be either a
165 notification or permission system for broad spectrum antibiotics.[33]

166 In England, IPC policy towards MRSA has evolved dramatically since 2001. It transformed from the
167 under-resourced 'Cinderella model' [34], [35], and HCAs being seen as unavoidable, to a vertical and
168 largely top-down performance management model. Mandatory surveillance and public reporting of
169 MRSA BSI cases in hospitals in 2001 was closely followed by national and local stretch targets, and
170 then embedded as 'objectives' in NHS operating/outcomes frameworks. More recently, the
171 approach has evolved to a 'zero tolerance' model strategically applied to avoidable HCAs with IPC
172 indicator basket (e.g. quality requirement, threshold, measurement methods, breach)[36]; and more
173 specifically for MRSA with post infection reviews being required to investigate how an incidence
174 occurred, and identify lessons and actions to prevent such instance from reoccurring in the future
175 [37].

176 Political pressure generated through a series of critical independent reports (e.g. National Audit
177 Office reports [35], Robert Francis Inquiry Reports into Mid-Staffordshire NHS Foundation Trust [38]),
178 and public outcry through increased media stories about dirty wards and hospital superbugs all acted
179 as drivers to this policy trajectory. Nurses and medical consultants within infection prevention teams
180 are required to have specialist training in infection prevention and cleanliness, set out within the
181 2015 Code of Practice in IPC [39].

182 **Table I** shows the timeline of key national policies reports and campaigns for addressing MRSA.

183

184 *(iii) Comparing approaches in Japan and England*

185 *Organisational structures*

186 At the organisational level, in the five Japanese hospitals reviewed here, Infection Control
187 Committees or Departments are positioned directly under the Hospital Director. In England, this
188 varies and includes examples of large teaching university hospitals where the IPC Committee sits
189 under the Clinical Effectiveness Committee, which in turns sits under the Hospital Board. In England,
190 the Directors of Infection Prevention & Control (DIPCs) can be members of the Hospital Board,
191 depending on their other organisational role. For example, if the DIPC is also Director of Nursing or
192 Medical Director, they are part of the Board. In Japan, nurse leadership in infection control is yet to
193 be seen.

194 England has developed multidisciplinary IPC teams, extending beyond health professionals, including
195 data managers/analysts and more recently surgical site infection (SSI) surveillance nurses and in
196 some cases decontamination leads, in alignment with the 2015 Code of Practice in IPC [39]. In Japan,
197 infection control also comprises multidisciplinary teams of health professionals, supported by admin
198 staff but unlike England do not also include dedicated data management support.

199

200 *The role of media*

201 Newspapers in Japan have often reported nosocomial infection cases which have resulted in deaths
202 but with little emphasis on AMR. Since 2016, however, AMR has become a worldwide problem and
203 has been taken up as an agenda at the G7 Summit, with national newspapers covering the topic. The
204 print and e-media has been publishing articles on the proper use of antibiotics and carrying out
205 awareness-raising activities for citizens [101]–[105].

206

207 *Comparison of interventions within and between countries*

208 The total number of interventions in the period 2000-17 was 322 in England, compared to 119 in
209 Japan. In England, there were two major peaks in the number of interventions around the periods of
210 2007/08 – 2008/09 and 2012/13 - 2013/14. The second peak was linked to a refocus on MRSA
211 through intense regulatory action combined with a series of persuasive, restrictive, and structural in
212 nature interventions. These included zero tolerance, mandatory post infection review for all MRSA
213 BSIs, financial penalties for hospitals breaching infection control standards, quality premiums (pay
214 for performance framework), together with a national strategy (the UK Five Year AMR Strategy 2013-

215 2018). In Japan, we see two large waves of sets of interventions introduced in 2007 and 2016
216 respectively. The magnitude of peaks in England is about two-fold greater than in Japan (Figure 3).

217 In England, there has been consistent focus on mandatory interventions, even after MRSA BSI rates
218 dropped significantly. In Japan, interventions were primarily recommendations with successive
219 increases observed 2013 onwards. Intensive focus on mandatory interventions in Japan was seen in
220 2007 and 2014 (Figure 4).

221 In both countries, campaigns started around the same time, but in England this type of intervention
222 peaked in the years 2007/8 -2008/9, while in Japan campaigns were concentrated in the years 2003-
223 2004 and then ten years later.

224 The target of campaigns in England has been wide, including health professionals, cleaning staff,
225 patients and the public. In Japan, national campaigns have been less prevalent, while the target
226 audience has often been narrower compared to England. For example, the Central Hospital Infection
227 Control Council launched a campaign in 2003 targeting medical professionals and municipalities,
228 excluding patients. Since publication of the AMR National Action Plan, however, campaigns have
229 broadened. This includes an informative website and educational activities for citizens using user
230 friendly SNS in response to calls from public institutions and non-profit organisations. The Japanese
231 government added new modules of drug-resistant bacteria and proper use of antimicrobials in the
232 curricula of medical schools in 2017. Furthermore, clinical seminars for doctors and dentists have
233 been held across the country. The government also established the National International Medical
234 Research Centre Hospital AMR Clinical Reference Centre (AMRCRC) in 2017.

235 In England, interventions have been primarily structural, though in more recent years the picture has
236 become more balanced with increasing emphasis also on persuasive and restrictive interventions.
237 Japan has tended toward proportionally more persuasive interventions, with focused efforts on
238 structural interventions in 2007 and 2014 (Figure 5).

239 England has implemented more interventions targeted at the national (macro) level than Japan.
240 England has also consistently, though to a lesser extent, also included micro-level focused
241 interventions, whereas Japan has focused primarily at interventions implemented at the
242 organisational (meso) level (Figure 6).

243 (iv) Wider contextual analysis

244 Distinctive features in each country are identified in the wider contextual policy domain which may
245 have impacted on the nature and scope of MRSA-related interventions and their implementation.

246 The speed of success in the reduction of MRSA infections may be explained by these factors and
247 approaches but causation of course cannot be attributed (Table II).

248

249 **Discussion**

250 In England there has been a substantial decrease in hospital MRSA BSIs in the last two decades,
251 though there is still no consensus in the literature about which types of interventions were primarily
252 responsible for bringing about this improvement; particularly as any such evaluation must also
253 consider effects on other organisms [3], [6], [116]. In Japan, despite multiple interventions
254 introduced and a notable decrease observed during the studied period, the prevalence of MRSA
255 infections in hospitals remains relatively high. It is helpful to take a longitudinal and contextually
256 grounded approach to such high-level comparative analysis. When comparing the availability and
257 feedback of data at the organisational level, there is a gap in the Japanese context with limited data
258 visualisation for the participating hospitals in the voluntary JANIS programme. It is difficult however
259 to predict the impact of a voluntary versus mandatory scheme of reporting. A preference for
260 national-level, mandatory and structural interventions in England reflects strong government
261 intervention and a mainly top-down approach. The public character of the NHS and its integrated
262 nature allowed for such an approach and resulted in a more uniform outcome at system-level. In
263 contrast, the Japanese health system being more decentralised and characterised by stronger
264 presence of the private sector emphasised recommendations and persuasive interventions targeting
265 hospitals. For example, the development of guidelines in Japan has been largely driven by academic
266 and professional societies, though lacking the next step of reinforcement and implementation via
267 government action (as is the case in England). The top-down enforced target setting and monitoring
268 approach in England has had very mixed responses from the professionals working within hospitals
269 [117].

270 Culturally, in Japan, the learning from the quality improvement movement in health and other
271 sectors advocates internal (to the organisation) drivers and motivators [118]. This is seen also in the
272 way that financial incentives (rather than punitive measures) for AMR interventions in Japan have
273 been used (e.g. medical reimbursement system). In contrast in England, enforced policies mandate
274 that the Chief Executive of the NHS Board is responsible for ensuring successful prevention and
275 control of hospital infections; all NHS trusts need to appoint a DIPC, while Chief Executives are held
276 personally responsible for the accuracy of infection data submitted by their trusts.

277 External international drivers seem to have influenced national activities particularly in Japan,
278 whereas England, particularly with key opinion leaders such as Chief Medical Officers, have tended
279 to take a leading role in a global scene influencing the development of Global Action Plan on AMR
280 and World Alliance for Patient Safety (i.e. worldwide hand hygiene and surgical checklist campaigns).
281 Alignment with WHO and other global interventions, such as the G7 Ise-Shima Summit 2016 and
282 Japan's National Action Plan on AMR seem to have led to increased national commitment by Prime
283 Minister, media attention, and citizen-targeted education.

284 It may be that an incremental approach to policy making [119] during short-term and unstable
285 governments, and strong influence of vested groups helps to explain Japan as a late adopter of
286 National Action Plans and other key policy interventions. In England, wider political windows of
287 opportunity, political leaning of national governments, and the government's determination to
288 combat MRSA appear to be reflected in the two peaks of interventions. For example, strong focus on
289 campaigns combined with NHS trust chief executives legal responsibility in MRSA (and CDI) reporting,
290 and more on mandatory requirements during 2007/8-2008/9 and 2012/13-2013/14 respectively.

291 In view of an increasing use of broad spectrum antimicrobials in Japan, some scholars suggest a
292 restrictive approach to the use of fluoroquinolones [120]. Possible longer-term impacts of restrictive
293 policy intervention on the reduction of MRSA through banning routine use of antibiotics has also
294 been discussed in the UK context [121]. A way forward for Japan may be to further nurture intrinsic
295 motivations and drivers with stable, supportive government combined with personal and
296 professional stewardship [122] and regional governance [123], given the complex involvement of
297 vested interest groups in policy making processes [124]. Additionally, if Japan were to shift from
298 confidential to public reporting of MRSA, its unintended consequences should be monitored [125].

299 The methods of healthcare funding and reimbursement mechanisms can influence antibiotic
300 prescription [126], hence consequently affecting AMR. In Japan, it is possible to induce the
301 implementation of healthcare by revising medical fees every two years. However, such system would
302 require commitment from hospital leads.

303 A higher level of healthcare utilisation and unique demographic shifts with falling birth rates to
304 contribute to healthcare funding for increasing aging population in Japan are also a reminder of
305 challenges which lay ahead. Addressing avoidable costs to healthcare are therefore a priority.

306 From a more sociological perspective, the relationship between national cultural values and
307 behaviour change in relation to IPC and antimicrobial stewardship needs to be investigated in Japan

308 where there are relatively higher power distance and uncertainty avoidance scores and slow
309 progress in the reduction of MRSA [127]–[129].

310 *Strengths and Limitations of the study.*

311 We looked at the trends and patterns of MRSA and the relevant interventions since 2000 in an
312 attempt to build and compare epidemiological settings across Japan and the UK, however direct
313 comparisons in numbers could not be made due to different reporting units used. We recognise the
314 difficulty of assessing the genuine effect of one specific intervention due to the concurrent existence
315 of interventions that are often multimodal. There are also limitations in capturing the degree,
316 duration and timing of implementation of interventions. Policy change and availability of new
317 diagnostic technologies are factors which may affect the volume of clinical specimens. These factors
318 are relevant for both Japan and England. There has been a high intensity of interventions in England
319 for antimicrobial stewardship and IPC compared to Japan. The very nature of surveillance comes
320 with limitations, and systems where a review process to verify infections and why they have
321 happened provides information for learning. Future research will address local level implementation
322 and perceptions of the interventions presented here through primary data (e.g. interviews with key
323 informants) to triangulate and/or understand local effects. Future work must also understand the
324 profile and trends in the community and across the whole health economy.

325 As an initial analysis, Leichter's four main dimensions of contextual factors are helpful for
326 understanding potential for transferability between countries, but a more detailed analysis of
327 governance approaches would be beneficial [3]. The approach here neglects the reality of complex
328 and dynamic social phenomena but provides a framework for future cross-national comparisons for
329 mutual learning.

330

331 **Conclusions**

332 In Japan, international drivers seem to have led to increased national commitment, but nationally,
333 the approach is characterised by voluntary surveillance and a more persuasive approach for clinical
334 professionals rather than a mandatory approach for institutional management. England has reached
335 the extremes of mandatory reporting and ever increasing information in the public domain.
336 Interventions need to be temporally relevant to the epidemiological trend, but also acceptable
337 within the health system, culture and public expectations. Lessons from other high-income countries
338 can help inform the right mix of interventions to create sustainable and resilient systems for future
339 infection and economic challenges.

340

341

342 Abbreviations

343 AMR, antimicrobial resistance; ARBI, Antimicrobial-Resistant Bacterial Infection; BSIs, bloodstream
344 infections; CCGs, Clinical Commissioning Groups; *C. difficile*, *Clostridium difficile*; CL, Clinical
345 Laboratory; CQUIN, Commissioning for Quality and Innovation; DH, Department of Health; DIPC,
346 Director of Infection Prevention and Control; *E. coli*, *Escherichia coli*; HCAs, healthcare-associated
347 infections; ICT, infection control team; IPC, infection prevention and control; JANIS, Japan
348 Nosocomial Infections Surveillance; MDROs, multidrug-resistant organisms; MHLW, Ministry of
349 Health, Labour and Welfare; MRSA, methicillin-resistant *Staphylococcus aureus*; NHS, National
350 Health Service; *S. aureus*, *Streptococcus aureus*; UK, United Kingdom.

351

352 Acknowledgements

353 We would like to thank the following people for participating in the shared learning meetings
354 supported by The Daiwa Anglo-Japanese Foundation: Dr Hironori Uematsu (Kyoto University, Japan).
355 Dr Enrique Castro-Sánchez, Juliet Allibone, Dr Gabriel Birgand, Dr Esmita Charani, Dr Céire Costelloe,
356 Dr Myriam Gharbi, Dr Monsey McLeod, Dr Timothy Miles Rawson (Imperial College London).

357

358 Conflict of interest statement

359 JAO is a consultant to Gama Healthcare, and has consulted for Pfizer in the past three years.

360

361 Funding source

362 This study was initiated through reciprocal UK-Japan visits in 2017, by researchers from Kyoto
363 University and Imperial College London sharing best practice in order to best address global
364 antimicrobial resistance, funded by The Daiwa Anglo-Japanese Foundation [Daiwa Foundation Award
365 8216/12167].

366 RA, NN, AH are supported by the National Institute for Health Research Health Protection Research
367 Unit (NIHR HPRU) [HPRU-2012-10047] in Healthcare Associated Infection and Antimicrobial
368 Resistance at Imperial College London in partnership with Public Health England. RA is supported by

369 NIHR Fellowship in knowledge mobilisation at Imperial College London. The views expressed are
370 those of the author(s) and not necessarily those of the National Health Service, the NIHR, the
371 Department of Health or Public Health England.

372

373 **References**

- 374 [1] World Health Organization. United Nations high-level meeting on antimicrobial resistance.
375 Geneva: WHO; 2016. Available at: [http://www.who.int/antimicrobial-](http://www.who.int/antimicrobial-resistance/events/UNGA-meeting-amr-sept2016/en/)
376 [resistance/events/UNGA-meeting-amr-sept2016/en/](http://www.who.int/antimicrobial-resistance/events/UNGA-meeting-amr-sept2016/en/) [last accessed April 2018].
- 377 [2] Meads G. Primary care in the twenty-first century: an international perspective. Abingdon:
378 Radcliffe Publishing Ltd; 2006.
- 379 [3] Birgand G, Castro-Sánchez E, Hansen S, Gastmeier P, Lucet JC, Ferlie E, et al. Comparison of
380 governance approaches for the control of antimicrobial resistance: analysis of three European
381 countries. *Antimicrob Resist Infect Control* 2018;7:28. doi: 10.1186/s13756-018-0321-5.
- 382 [4] Department of Health. UK Five Year Antimicrobial Resistance Strategy 2013 to 2018. London:
383 DH; 2013. Available at: [https://www.gov.uk/government/publications/uk-5-year-](https://www.gov.uk/government/publications/uk-5-year-antimicrobial-resistance-strategy-2013-to-2018)
384 [antimicrobial-resistance-strategy-2013-to-2018](https://www.gov.uk/government/publications/uk-5-year-antimicrobial-resistance-strategy-2013-to-2018) [last accessed April 2018].
- 385 [5] The Government of Japan. National Action Plan on Antimicrobial Resistance (AMR): 2016-
386 2020. Tokyo: The Government of Japan; 2016. Available at: [http://www.mhlw.go.jp/file/06-](http://www.mhlw.go.jp/file/06-Seisakujouhou-10900000-Kenkoukyoku/0000138942.pdf)
387 [Seisakujouhou-10900000-Kenkoukyoku/0000138942.pdf](http://www.mhlw.go.jp/file/06-Seisakujouhou-10900000-Kenkoukyoku/0000138942.pdf) [last accessed April 2018].
- 388 [6] Holmes A. Infection prevention and control: lessons from acute care in England: towards a
389 whole health economy approach. London: Health Foundation; 2015. Available at:
390 [https://www.health.org.uk/publication/infection-prevention-and-control-lessons-acute-care-](https://www.health.org.uk/publication/infection-prevention-and-control-lessons-acute-care-england)
391 [england](https://www.health.org.uk/publication/infection-prevention-and-control-lessons-acute-care-england) [last accessed April 2018].
- 392 [7] Duerden B, Fry C, Johnson AP, Wilcox MH. The control of methicillin-resistant *Staphylococcus*
393 *aureus* blood stream infections in England. *Open Forum Infect Dis* 2015;1–8.
- 394 [8] Public Health England (formerly HPA). Results from the mandatory surveillance of MRSA
395 bacteraemia. PHE; 2014. Available at:
396 [http://webarchive.nationalarchives.gov.uk/20140714084352/http://www.hpa.org.uk/web/H](http://webarchive.nationalarchives.gov.uk/20140714084352/http://www.hpa.org.uk/web/HPAweb&HPAwebStandard/HPAweb_C/1233906819629)
397 [PAweb&HPAwebStandard/HPAweb_C/1233906819629](http://webarchive.nationalarchives.gov.uk/20140714084352/http://www.hpa.org.uk/web/HPAweb&HPAwebStandard/HPAweb_C/1233906819629) [last accessed April 2018].
- 398 [9] Public Health England. Statistics - MRSA bacteraemia: annual data. PHE; 2017. Available at:

- 399 <https://www.gov.uk/government/statistics/mrsa-bacteraemia-annual-data> [last accessed
400 April 2018].
- 401 [10] Public Health England. Statistics - MSSA bacteraemia: annual data. PHE; 2017. Available at:
402 <https://www.gov.uk/government/statistics/mssa-bacteraemia-annual-data> [last accessed
403 April 2018].
- 404 [11] Public Health England. Statistics -Escherichia coli (E. coli) bacteraemia: annual data. PHE;
405 2017. Available at: [https://www.gov.uk/government/statistics/escherichia-coli-e-coli-](https://www.gov.uk/government/statistics/escherichia-coli-e-coli-bacteraemia-annual-data)
406 [bacteraemia-annual-data](https://www.gov.uk/government/statistics/escherichia-coli-e-coli-bacteraemia-annual-data) [last accessed April 2018].
- 407 [12] Public Health England. Statistics - Clostridium difficile infection: annual data. PHE; 2017.
408 Available at: [https://www.gov.uk/government/statistics/clostridium-difficile-infection-](https://www.gov.uk/government/statistics/clostridium-difficile-infection-annual-data)
409 [annual-data](https://www.gov.uk/government/statistics/clostridium-difficile-infection-annual-data) [last accessed April 2018].
- 410 [13] National Institute of Infectious Diseases (NIID). Methicillin-resistant Staphylococcus aureus
411 infections. IDWR 2002:18.
- 412 [14] Japan Nosocomial Infections Surveillance (JANIS). About JANIS. Tokyo: MHLW. Available at:
413 <https://janis.mhlw.go.jp/english/about/index.html> [last accessed June 2018].
- 414 [15] Japan Nosocomial Infections Surveillance (JANIS). Open Information. Tokyo: MHLW. Available
415 at: <https://janis.mhlw.go.jp/report/index.html> [last accessed June 2018].
- 416 [16] Dar OA, Hasan R, Schlundt J, Harbarth S, Caleo G, Dar FK, et al. Exploring the evidence base
417 for national and regional policy interventions to combat resistance. *Lancet*
418 2016;387(10015):285-95.
- 419 [17] Institute of Medicine. To err is human: building a safer health system. Washington, DC:
420 National Academies Press; 1999.
- 421 [18] Committee on Quality of Health Care in America, Institute of Medicine. Crossing the quality
422 chasm: a new health system for the 21st Century. Washington, DC: National Academies
423 Press;2001.
- 424 [19] Kyratsis Y, Ahmad R, Hatzaras K, Iwami M, Holmes A. Making sense of evidence in
425 management decisions: the role of research-based knowledge on innovation adoption and
426 implementation in health care. *Heal Serv Deliv Res* 2014;2. doi:10.3310/hsdr02060.
- 427 [20] Boyce T, Murray E, Holmes A. What are the drivers of the UK media coverage of meticillin-
428 resistant Staphylococcus aureus, the inter-relationships and relative influences? *J Hos. Infect*

- 429 2009;73(4):400–407.
- 430 [21] Donyai P, Okafor S, Virgo R, Amin K, Nasr M. Messages about antibiotic resistance in different
431 newspaper genres. *Pharmacy* 2013;1(2):181-192.
- 432 [22] Collins LC, Jaspal R, Nerlich B. Who or what has agency in the discussion of antimicrobial
433 resistance in UK news media (2010 – 2015)? A transitivity analysis. *Health* 2017. doi:
434 10.1177/1363459317715777.
- 435 [23] Zingg W, Holmes A, Dettenkofer M, Goetting T, Secci F, Clack L, et al. Hospital organisation,
436 management, and structure for prevention of health-care-associated infection: a systematic
437 review and expert consensus. *Lancet Infect Dis* 2015;15(2):212–224.
- 438 [24] World Health Organization. Guidelines on core components of infection prevention and
439 control programmes at the national and acute health care facility level. Geneva: WHO; 2016.
- 440 [25] Storr J, Twyman A, Zingg W, Damani N, Kilpatrick C, Reilly J, et al. Core components for
441 effective infection prevention and control programmes: new WHO evidence-based
442 recommendations. *Antimicrob Resist Infect Control* 2017;6:6. doi: 10.1186/s13756-016-0149-
443 9.
- 444 [26] Iwami M, Ahmad R, Castro-Sánchez E, Birgand G, Johnson AP, Holmes A. Capacity of English
445 NHS hospitals to monitor quality in infection prevention and control using a new European
446 framework: a multilevel qualitative analysis. *BMJ Open* 2017;7(1):e012520. doi:
447 10.1136/bmjopen-2016-012520.
- 448 [27] Davey P, Brown E, Charani E, Fenelon L, Gould IM, Holmes A, et al. Interventions to improve
449 antibiotic prescribing practices for hospital inpatients (review). *Cochrane Database Syst Rev*
450 2013;(4):CD003543. doi: 10.1002/14651858.CD003543.pub3.
- 451 [28] Naylor NR, Zhu N, Hulscher M, Holmes A, Ahmad R, Robotham JV. Is antimicrobial
452 stewardship cost-effective? A narrative review of the evidence. *Clin Microbiol Infect*
453 2017;23(11):806-811.
- 454 [29] Leichter H. A comparative approach to policy analysis: health care policy in four nations.
455 Cambridge: Cambridge University Press; 1979.
- 456 [30] Public Health England. English Surveillance Programme for Antimicrobial Utilisation and
457 Resistance (ESPAUR): Report 2017. London: PHE; 2017.
- 458 [31] European Centre for Disease Prevention and Control. Surveillance of antimicrobial resistance

- 459 in Europe 2016. Annual Report of the European Antimicrobial Resistance Surveillance
460 Network (EARS-Net). Stockholm: ECDC; 2017.
- 461 [32] World Health Organization. Antimicrobial resistance: global report on surveillance. Geneva:
462 WHO; 2014.
- 463 [33] Suzuki A, Kobayashi H. The history of infection control and prevention in Japan. *J Heal Infect*
464 2015;8:1–9.
- 465 [34] Department of Health. Getting ahead of the curve: action to strengthen the microbiology
466 function in the prevention and control of infectious diseases. London: DH; 2002. Available at:
467 http://webarchive.nationalarchives.gov.uk/20130107105354/http://www.dh.gov.uk/prod_consum_dh/groups/dh_digitalassets/@dh/@en/documents/digitalasset/dh_4060336.pdf [last
468 accessed April 2018].
- 470 [35] National Audit Office. Improving patient care by reducing the risk of hospital acquired
471 infection: a progress report. London: NAO; 2004.
- 472 [36] Royal College of Nursing (RCN) and Infection Prevention Society (IPS). Infection prevention
473 and control commissioning toolkit: guidance and information for nursing and commissioning
474 staff in England. London and Seaford: RCN and IPS; 2012.
- 475 [37] NHS Commissioning Board. Everyone counts: planning for patients 2013/14. NHS
476 Commissioning Board; 2012.
- 477 [38] Francis R QC. Independent Inquiry into care provided by Mid Staffordshire NHS Foundation
478 Trust January 2005 – March 2009. London: The Stationery Office; 2010. available at:
479 <https://www.gov.uk/government/publications/independent-inquiry-into-care-provided-by-mid-staffordshire-nhs-foundation-trust-january-2001-to-march-2009> [last accessed April
480 2018].
- 482 [39] Public and International Health Directorate, Health Protection and Emergency Response
483 Division, Infectious Diseases Branch 10200. The Health and Social Care Act 2008: Code of
484 Practice on the prevention and control of infections and related guidance. London: DH; 2015.
- 485 [40] Department of Health. HSC 2000/002: The management and control of hospital infection -
486 Action for the NHS for the management and control of infection in hospitals in England.
487 London: DH; 2000.
- 488 [41] Ministry of Health, Labour and Welfare (MHLW). Evaluation of infection control measures:

- 489 remuneration of medical reimbursement system. Tokyo: MHLW; 2000.
- 490 [42] Department of Health. UK antimicrobial resistance strategy and action plan. London: DH;
491 2000.
- 492 [43] Infection Control Doctor (ICD) council. 1999. Available at: <http://www.icdjc.jp/> [last accessed
493 Janaury 2018].
- 494 [44] Department of Health. The NHS plan - A plan for investment, a plan for reform. London: The
495 Stationary Office Limited; 2000. Available at:
496 [http://webarchive.nationalarchives.gov.uk/+http://www.dh.gov.uk/en/Publicationsandstatist
497 tics/Publications/PublicationsPolicyAndGuidance/DH_4002960](http://webarchive.nationalarchives.gov.uk/+http://www.dh.gov.uk/en/Publicationsandstatistics/Publications/PublicationsPolicyAndGuidance/DH_4002960) [last accessed April 2018].
- 498 [45] Department of Health. Chief Medical Officer's Update 30: surveillance of healthcare
499 associated infections. London: DH; 2001. Available at:
500 [http://webarchive.nationalarchives.gov.uk/20130107105354/http://www.dh.gov.uk/prod_co
501 nsum_dh/groups/dh_digitalassets/@dh/@en/documents/digitalasset/dh_4013652.pdf](http://webarchive.nationalarchives.gov.uk/20130107105354/http://www.dh.gov.uk/prod_consum_dh/groups/dh_digitalassets/@dh/@en/documents/digitalasset/dh_4013652.pdf) [last
502 accessed April 2018].
- 503 [46] NHS Estates. National standards of cleanliness for the NHS. London: NHS EStates; 2001.
- 504 [47] Okubo T. Background and evolution of measures and policies associated with infection
505 prevention and control in Japan. *Japanese J Infect Prev Control* 2016;31(4):213–23.
- 506 [48] NHS Estates. Infection control in the built environment: design and planning. London: NHS
507 Estates; 2002.
- 508 [49] Chief Medical Officer. Winning ways: working together to reduce healthcare associated
509 infection in England. London: DH; 2003. Available at:
510 [http://webarchive.nationalarchives.gov.uk/+http://www.dh.gov.uk/en/Publicationsandstatist
511 tics/Publications/PublicationsPolicyAndGuidance/DH_4064682](http://webarchive.nationalarchives.gov.uk/+http://www.dh.gov.uk/en/Publicationsandstatistics/Publications/PublicationsPolicyAndGuidance/DH_4064682) [last accessed April 2018].
- 512 [50] Ministry of Health, Labour and Welfare. Infectious Disease Act on prevention of infectious
513 diseases and medical care for patients with infectious diseases. Tokyo: MHLW; 2003.
- 514 [51] Ministry of Health, Labour and Welfare. Details about the Central Conference on Infection
515 Control in Hospital. Tokyo: MHLW; 2005.
- 516 [52] Department of Health. Towards cleaner hospitals and lower rates of infection - a summary of
517 action. London: DH; 2004.
- 518 [53] Department of Health. National standards, local action health and social care standards and

- 519 planning framework (2005/06–2007/08). Leeds: DH; 2004.
- 520 [54] National Patient Safety Agency (NPSA). About the cleanyourhands campaign. NPSA; 2011.
521 Available at: <http://www.npsa.nhs.uk/cleanyourhands/about-us/>. [last accessed August
522 2015].
- 523 [55] Department of Health. Bloodborne MRSA infection rates to be halved by 2008 - Press notice.
524 London: 2004.
- 525 [56] Ministry of Health, Labour and Welfare. Revision of 'Regulation for enforcement of Medical
526 Care Act'. Tokyo: MHLW; 2005.
- 527 [57] Chief Medical Officer and Chief Nursing Officer. Saving Lives: a delivery programme to reduce
528 healthcare associated infection including MRSA. DH; 2005. Available at:
529 http://webarchive.nationalarchives.gov.uk/20130107105354/http://www.dh.gov.uk/prod_consum_dh/groups/dh_digitalassets/@dh/@en/documents/digitalasset/dh_4113194.pdf [last
530 accessed April 2018].
531
- 532 [58] Ministry of Health, Labour and Welfare. Notice of 'Prevention of nosocomial infection in
533 medical facilities'. Tokyo: MHLW; 2005.
- 534 [59] Department of Health. Introduction of the mandatory MRSA bacteraemia enhanced
535 surveillance scheme. London: DH; 2005.
- 536 [60] Central Conference on Infection Control in Hospital, Ministry of Health, Labour and Welfare.
537 On the arrangement of full-time nosocomial infection counterparts in specific function
538 hospitals. Tokyo: MHLW; 2005. Available at: [http://www.mhlw.go.jp/shingi/2005/01/s0113-
539 6c.html#top](http://www.mhlw.go.jp/shingi/2005/01/s0113-6c.html#top) [last accessed April 2018].
- 540 [61] Ministry of Health, Labour and Welfare. Evaluation of infection control measures:
541 remuneration of medical fee reimbursement system. Tokyo: MHLW; 2006.
- 542 [62] Department of Health. Reporting MRSA data: overview of arrangements. Professional letter
543 from the Chief Medical Officer and Chief Nursing Officer. (PL/CMO/2006/2, PL/CNO/2006/2).
544 London: DH; 2006.
- 545 [63] Department of Health - MRSA/Cleaner Hospitals Programme. Going further faster:
546 implementing the Saving Lives delivery programme - Sustainable change for cleaner, safer
547 care. London: DH; 2006.
- 548 [64] Parliament of the UK Health Act 2006 (c. 28). 2006.

- 549 [65] Department of Health. The Health Act 2006: Code of Practice for the prevention and control
550 of healthcare associated infections. London: DH; 2006.
- 551 [66] Department of Health. Our NHS, our future: NHS next stage review interim report. London:
552 DH; 2007.
- 553 [67] Health Policy Bureau, Ministry of Health, Labour and Welfare. For the enforcement of the
554 revised Infectious Diseases Control Law. Tokyo: MHLW; 2007. Available at:
555 <https://www.niid.go.jp/niid/images/idsc/kikikanri/H28/12-3.pdf> [last accessed January 2017].
- 556 [68] Department of Health. Uniforms and workwear: an evidence base for developing local policy.
557 Leeds: DH; 2007.
- 558 [69] Health Policy Bureau, Ministry of Health, Labour and Welfare. Regarding the enforcement of
559 the law to revise some of the Medical Care Act, Japan. Tokyo: MHLW; 2007.
- 560 [70] Ministry of Health, Labour and Welfare. Guide and training programme of medical safety
561 manager. Tokyo: MHLW; 2007.
- 562 [71] Department of Health. Saving Lives: reducing infection, delivering clean and safe care -
563 isolating patients with healthcare-associated infection: a summary of best practice. DH; 2007.
- 564 [72] Ministry of Health, Labour and Welfare. Measures to prevent in-hospital infection by drug-
565 resistant bacteria and responses after occurrence. Tokyo: MHLW; 2007.
- 566 [73] Chief Nursing Officer/Director General of Finance. PL CNO (2007)6: Improving cleanliness and
567 infection control. Department of Health; 2007. Available at:
568 http://webarchive.nationalarchives.gov.uk/+http://www.dh.gov.uk/en/Publicationsandstatistics/Lettersandcirculars/Professionalletters/Chiefnursingofficerletters/DH_080053 [last
569 accessed April 2018].
570
- 571 [74] Department of Health. The Operating Framework for 2009/10 for the NHS in England.
572 London: DH; 2008.
- 573 [75] Japanese Healthcare Associated Infections Surveillance Committee. Japanese Healthcare
574 Associated Infections Surveillance Committee. 2017. Available at:
575 http://www.kankyokansen.org/modules/iinkai/index.php?content_id=4. [last accessed
576 January 2018].
- 577 [76] Department of Health. Clean, safe care: reducing infections and saving lives. London: DH;
578 2008.

- 579 [77] Parliament of the UK Health and Social Care Act 2008 (c. 14). 2008.
- 580 [78] Department of Health. MRSA screening - operational guidance 2. 2008. Available at:
581 http://webarchive.nationalarchives.gov.uk/20130123180013/http://www.dh.gov.uk/en/Publicationsandstatistics/Lettersandcirculars/Dearcolleagueletters/DH_092844 [last accessed April
582 2018].
- 584 [79] Department of Health. MRSA objective for 2010-11. DH; 2009. Available at:
585 http://webarchive.nationalarchives.gov.uk/20130107105354/http://www.dh.gov.uk/en/Publicationsandstatistics/Publications/PublicationsPolicyAndGuidance/DH_109951 [last accessed
586 April 2009].
- 588 [80] Ministry of Health, Labour and Welfare. Evaluation of infection control measures:
589 remuneration of medical fee reimbursement system. Tokyo: MHLW; 2010.
- 590 [81] Department of Health. MRSA screening - operational guidance 3. DH; 2010. Available at:
591 http://webarchive.nationalarchives.gov.uk/20130123181012/http://www.dh.gov.uk/en/Publicationsandstatistics/Lettersandcirculars/Dearcolleagueletters/DH_114961 [last accessed April
592 2018].
- 594 [82] Ministry of Health, Labour and Welfare. About nosocomial infection control measures in
595 medical institutions. Tokyo: MHLW; 2011.
- 596 [83] Department of Health's advisory committee on Antimicrobial Resistance and Healthcare
597 Associated Infection (ARHAI). Antimicrobial stewardship: 'Start smart - then focus'. London:
598 DH; 2011.
- 599 [84] Ministry of Health, Labour and Welfare. Evaluation of infection control measures:
600 remuneration of medical reimbursement system. Tokyo: MHLW; 2012.
- 601 [85] MRSA Infection Guideline Preparation Committee. Guideline for treatment of MRSA infection.
602 Japanese Association for Infectious Diseases/Japanese Society of Chemotherapy; 2013.
603 Available at: http://www.chemotherapy.or.jp/guideline/guideline_mrsa.pdf [last accessed
604 January 2018].
- 605 [86] Davies SC. Annual report of the Chief Medical Officer, Volume Two, 2011, Infections and the
606 rise of antimicrobial resistance. London: DH; 2013. Available at:
607 [https://www.gov.uk/government/uploads/system/uploads/attachment_data/file/138331/C](https://www.gov.uk/government/uploads/system/uploads/attachment_data/file/138331/CMO_Annual_Report_Volume_2_2011.pdf)
608 [MO_Annual_Report_Volume_2_2011.pdf](https://www.gov.uk/government/uploads/system/uploads/attachment_data/file/138331/CMO_Annual_Report_Volume_2_2011.pdf) [last accessed April 2018].

- 609 [87] NHS England. Quality Premium: 2013/14 guidance for CCGs: Final – March 2013. Leeds: NHS
610 England; 2013.
- 611 [88] NHS England. Everyone counts: planning for patients 2014/15 - 2018/19. Leeds: NHS England;
612 2013.
- 613 [89] NHS England. NHS Standard Contract 2014/15 Particulars. NHS England; 2013. Available at:
614 <https://www.england.nhs.uk/wp-content/uploads/2013/12/sec-a-part-1415.pdf> [last
615 accessed April 2018].
- 616 [90] Regional Medical Care Plan Division, Health Policy Bureau, Ministry of Health, Labour and
617 Welfare. On measures to prevent in-hospital infection in medical institutions. Tokyo: MHLW;
618 2014. Available at: <https://www.pref.aichi.jp/uploaded/attachment/44155.pdf> [last accessed
619 April 2018].
- 620 [91] Department of Health expert advisory committee on Antimicrobial Resistance and Healthcare
621 Associated Infection (ARHAI) MRSA Screening Implementation Group. Implementation of
622 modified admission MRSA screening guidance for NHS. London: ARHAI; 2014.
- 623 [92] Public Health Engand. English surveillance programme for antimicrobial utilisation and
624 resistance (ESPAUR) Report 2014. London: PHE; 2014.
- 625 [93] Public Health Engand. English surveillance programme for antimicrobial utilisation and
626 resistance (ESPAUR) 2010 to 2014: Report 2015. London: PHE; 2015.
- 627 [94] Become an Antibiotic Guardian. 2018. Available at: <http://antibioticguardian.com/> [last
628 accessed June 2018].
- 629 [95] Ministry of Health, Labour and Welfare. Central Conference on Nosocomial Infection Control,
630 Ministry of Health. Recommendations on measures against drug-resistant bacteria. Tokyo:
631 MHLW; 2015.
- 632 [96] Cabinet Office. National Risk Register of Civil Emergencies 2015. London: Cabinet Office;
633 2015.
- 634 [97] Beech E (Healthcare Acquired Infection and Antimicrobial Resistance Project Lead at NHS
635 England). Introduction to the antibiotic Quality Premium. NHS England; 2015. Available at:
636 [https://www.england.nhs.uk/wp-content/uploads/2015/04/02-amr-lon-intro-antimicrobial-](https://www.england.nhs.uk/wp-content/uploads/2015/04/02-amr-lon-intro-antimicrobial-prescribing-qp.pdf)
637 [prescribing-qp.pdf](https://www.england.nhs.uk/wp-content/uploads/2015/04/02-amr-lon-intro-antimicrobial-prescribing-qp.pdf) [last accessed April 2018].
- 638 [98] NHS England. Commissioning for Quality and Innovation (CQUIN) Guidance for 2016/17. NHS

- 639 England; 2016.
- 640 [99] Public Health England. AMR local indicators. PHE. Available at:
641 <https://fingertips.phe.org.uk/profile/amr-local-indicators> [last accessed April 2018].
- 642 [100] The Japanese Association for Infectious Diseases/ Japanese Society of Chemotherapy.
643 Guideline for treatment of MRSA infection. 2nd edition. Japanese Association for Infectious
644 Diseases/Japanese Society of Chemotherapy; 2017.
- 645 [101] Editorial: Spread the antibiotic correct usage. The Asahi Shimbun, Japan. 3 May 2017, p. 18.
- 646 [102] To take correct medicine, to prevent the increase in resistant bacteria appealed by cartoon
647 character. The Asahi Shimbun, Japan. 2 December 2017, p. 3.
- 648 [103] Opinion: behind the scenes / drug-resistant bacteria needs urgent action. The Yomiuri
649 Shimbun. 20 September 2016, p. 5.
- 650 [104] Resistant bacteria, even antibiotics even if familiar disease difficult treatment. The Asahi
651 Shimbun, Japan. 8 February 2017, p. 29.
- 652 [105] "Got sick of going to the hospital!" The document 'Nosocomial infection'. Weekly Gendai,
653 Japan. 12 July 2016.
- 654 [106] World Bank. Indicators. Available at: <http://data.worldbank.org/indicator> [last accessed April
655 2018].
- 656 [107] World Health Organization. Global Health Estimates 2016 Summary Tables. Geneva: WHO;
657 2018. Available at: http://www.who.int/healthinfo/global_burden_disease/estimates/en/
658 [last accessed April 2018].
- 659 [108] OECD iLibrary. Health statistics: health care utilisation. OECD; 2018. Available at:
660 [https://www.oecd-ilibrary.org/social-issues-migration-health/data/oecd-health-
661 statistics/oecd-health-data-health-care-utilisation_data-00542-
662 en?parentId=http%3A%2F%2F](https://www.oecd-ilibrary.org/social-issues-migration-health/data/oecd-health-statistics/oecd-health-data-health-care-utilisation_data-00542-en?parentId=http%3A%2F%2F) [last accessed April 2018].
- 663 [109] OECD iLibrary. Health at a Glance 2017: OECD indicators. OECD; 2017. Available at:
664 http://dx.doi.org/10.1787/health_glance-2017-en [last accessed April 2018].
- 665 [110] Papanicolas I, Woskie LR, Jha AK. Health care spending in the United States and other high-
666 income countries. JAMA 2018;319(10):1024–1039.
- 667 [111] Beck M, Melo S. Quality management and managerialism in healthcare: a critical historical

- 668 survey. Basingstoke: Palgrave MacMillan; 2014.
- 669 [112] Böhm K, Schmid A, Götze R, Landwehr C, Rothgang H. Five types of OECD healthcare systems:
670 empirical results of a deductive classification. *Health Policy* 2013;113(3):258–269.
- 671 [113] Mossialos E, Djordjevic A, Osborn R, Sarnak D (eds.). *International profiles of health care*
672 *systems*. New York; Washington, DC: The Commonwealth Fund; 2017. Available at:
673 [http://www.commonwealthfund.org/publications/fund-reports/2017/may/international-](http://www.commonwealthfund.org/publications/fund-reports/2017/may/international-profiles)
674 [profiles](http://www.commonwealthfund.org/publications/fund-reports/2017/may/international-profiles) [last accessed April 2018].
- 675 [114] Hofstede Insights. *Compare countries*. Helsinki: Hofstede Insights; 2018. Available at:
676 <https://www.hofstede-insights.com/product/compare-countries/> [last accessed April 2018].
- 677 [115] Hofstede Insights. *The 6 dimensions of national culture*. Helsinki: Hofstede Insights; 2018.
678 Available at: <https://www.hofstede-insights.com/models/national-culture/> [last accessed
679 April 2018].
- 680 [116] Septimus E, Weinstein RA, Perl TM, Goldmann DA, Yokoe DS. Approaches for preventing
681 healthcare-associated infections: go long or go wide? *Infect Control Hosp Epidemiol*
682 2014;35(7):797–801.
- 683 [117] Brewster L, Tarrant C, Dixon-Woods M. Qualitative study of views and experiences of
684 performance management for healthcare-associated infections. *J Hosp Infect* 2016;94(1):41–
685 47.
- 686 [118] Baghel NBA. An overview of continuous improvement: from the past to the present. *Manag*
687 *Decis* 2005;43(5):761-771.
- 688 [119] Reich MR, Ikegami N, Shibuya K, Takemi K. 50 years of pursuing a healthy society in Japan.
689 *Lancet* 2011;378(9796):1051–1053, 2011.
- 690 [120] Tsutsui A, Yahara K, Shibayama K. Trends and patterns of national antimicrobial consumption
691 in Japan from 2004 to 2016. *J Infect Chemother* 2018; pii: S1341-321X(18)30008-4. doi:
692 10.1016/j.jiac.2018.01.003.
- 693 [121] Dancer SJ, Kirkpatrick P, Corcoran DS, Christison F, Farmer D, Robertson C. Approaching zero:
694 temporal effects of a restrictive antibiotic policy on hospital-acquired *Clostridium difficile*,
695 extended-spectrum β -lactamase-producing coliforms and meticillin-resistant *Staphylococcus*
696 *aureus*. *Int J Antimicrob Agents* 2013;41(2):137-142.
- 697 [122] Meads G. Presentation at the 1st Shared Learning Meeting, Daiwa project. Imperial College

- 698 London. 24 January 2017.
- 699 [123] Hashimoto H, Ikegami N, Shibuya K, Izumida N, Noguchi H, Yasunaga H, et al. Cost
700 containment and quality of care in Japan: is there a trade-off? *Lancet* 2011;378(9797):1174–
701 1182.
- 702 [124] Mori R, Takemi K, Fineberg HV. Science and consensus for health policy making in Japan.
703 *Lancet* 2012;379(9810):12–13.
- 704 [125] Hausteiner T, Gastmeier P, Holmes A, Lucet JC, Shannon RP, Pittet D, et al. Use of benchmarking
705 and public reporting for infection control in four high-income countries. *Lancet Infect Dis*
706 2011;11(6):471–81.
- 707 [126] Hulscher ME, Grol RP, van der Meer JW. Antibiotic prescribing in hospitals: a social and
708 behavioural scientific approach. *Lancet Infect Dis* 2010;10(3):167–175.
- 709 [127] Deschepper R, Grigoryan L, Lundborg CS, Hofstede G, Cohen J, Kelen GV, et al. Are cultural
710 dimensions relevant for explaining cross-national differences in antibiotic use in Europe? *BMC*
711 *Health Serv Res* 2008;8:123. doi: 10.1186/1472-6963-8-123.
- 712 [128] Borg MA, Camilleri L, Waisfisz B. Understanding the epidemiology of MRSA in Europe: do we
713 need to think outside the box? *J Hosp Infect* 2012;81(4):251–256.
- 714 [129] Borg MA. Lowbury Lecture 2013. Cultural determinants of infection control behaviour:
715 understanding drivers and implementing effective change. *J Hosp Infect* 2014;86(3):161–8.
716

TABLES

ACCEPTED MANUSCRIPT

Table 1

Comparison of the overview of key policies, guidelines, reports, and campaigns for MRSA and other relevant interventions between Japan and England.

Japan	Year	England
Introduction of nation-wide voluntary surveillance (JANIS) – MHLW [14].	2000	DH issued Health Service Circular 2000/002: The management and control of hospital infection: action for the NHS for the management and control of infection in Hospitals in England [40].
Revision of medical reimbursement system: Hospital without ICT would subtracted fees (0.5 US\$ or £0.4) – MHLW [41].		DH issued UK antimicrobial resistance strategy and action plan [42].
First Infection Control Doctors were certified. [43]		DH issued, The NHS Plan - A plan for investment, a plan for reform. Star ratings to be introduced. National cleaning standards to be monitored by Patient Environment Action Teams (PEAT). 'Modern matrons' to have the authority at ward level to ensure hospital cleanliness and right care for patients. A trust board member to be nominated to assume responsibility to monitor hospital cleanliness and report regularly to the board. [44]
18 Nurses certified as first Infection Control Nurses [33].	2001	Introduction of mandatory surveillance for MRSA BSIs [45].
Inauguration of the MHLW.		NHS Estates issued National Standards of Cleanliness for the NHS for the first time [46].
Held an expert opinion meeting on hospital infection control [47].	2002	The first results for MRSA mandatory surveillance data (April 2001 - September 2001) published in February 2002.
		Infection control in the built environment: design and planning, published by NHS Estates. Emphasised the importance of involvement of health staff and infection control teams in designing and planning of health facilities.[48]
'Future measures for nosocomial infection control' was released by expert opinion meeting on hospital infection control - Construction of a grand design for nationwide nosocomial infection control. The organisation the tasks from each stakeholder [47].	2003	DH issued Winning ways: working together to reduce healthcare associated infection in England, a report from the Chief Medical Officer [49].
Revised Act on the Prevention of Infectious Diseases and Medical Care for Patients with Infectious Diseases was released [50].		
'Central Conference on Infection Control in Hospital' was established as a permanent advisory body by MHLW [51].	2004	Mandatory surveillance of orthopaedic surgical site infections began in trusts.
		DH issued Towards cleaner hospitals and lower rates of infection: a summary of action [52]. Patients were concerned about poor hospital cleanliness and increasing MRSA infections.
		National standards, local action: Health and Social Care Standards and Planning Framework 2005/2006–2007/2008 [53].
		National Patient Safety Agency launched cleanyourhands campaign to implement near patient alcohol hand rubs [54]. First in the world.
		National target reduction for the number of incidents of MRSA BSIs by 50% over 3 year period (April 2005 – March 2008) compared to the 2003/04 baseline data [55]. Mandatory target introduced to hospitals in November 2004.
		All NHS trusts to appoint a DIPC, who has authority and responsibility for the reduction of HCAs (e.g., directly reporting to the trust chief executive and trust board, writing and publishing an annual report on HCAs).[49]
Revision of 'Regulation for Enforcement of Medical Care Act' – MHLW [56].	2005	DH issued Saving Lives: a delivery programme to reduce healthcare associated infection including MRSA [57]. The first version of Saving Lives programme. Saving Lives campaign, including High Impact Interventions based on the 'care bundle' principle.
'Prevention of in-hospital infection in medical facilities' was released by MHLW [58]. Points which regard nosocomial infection prevention based on the latest scientific evidence.		Introduction of Mandatory MRSA bacteraemia enhanced surveillance scheme [59]. Health protection Agency developed and introduced an enhanced MRSA reporting system, moving from aggregated acute trust level to patient-level data collection using web-based Data Capture

Japan	Year	England
		System with 'real-time' nature, and that enabled to identify the presence of the BSI on admission.
Mandatory assignment of dedicated infection control personnel at Advanced Treatment Hospitals [47], [56], [60].		
Revision of medical reimbursement system: Hospital with medical safety measures could receive additional fees (4.7 US\$ or £3.3)[61].	2006	The Chief Medical Officer made chief executive of the NHS trust board personally responsible for the accuracy of infection data submitted by their trusts [62].
		DH issued Going further faster: implementing the Saving Lives delivery programme - Sustainable change for cleaner, safer care. Set out actions aimed to reduce MRSA, and in turn, support system-wide improvement in HCAs (e.g. ensuring infection control (induction & ongoing) training for hospital staff, inclusion of infection control in job description).[63]
		Health Act 2006 (c.28), requirement for provider registration with regulator, legal requirement for providers to ensure protection against HCAs [64].
		Health Act 2006: Code of Practice for the prevention and control of healthcare associated infections issued [65]. Known as The 'Hygiene Code', applied to all NHS healthcare providers. Improvement Notice from the regulatory body for failing to observe the Code, or special measures for significant failings.
		DH's Healthcare Associated Infection Improvement Team established, and paid visits to acute hospitals to help trusts reduce MRSA BSIs. Doubled the size of the expert Improvement Team by October 2007 when Lord Darzi's interim report released. [66]
Partial revision of Infectious Disease Act – Tuberculosis prevention law was integrated into this act [67].	2007	DH published Uniforms and workwear: an evidence base for developing local policy [68]. Known as the 'bare below the elbows' guidance.
Partial revision law for the revision of Medical Care Act enacted- This law was obligatory for all medical institutions to establish measures to prevent in-hospital infection [69].		The Secretary of State for Health announced a series of measures to combat HCAs, including a legal requirement for NHS trusts chief executives to report MRSA BSIs (and CDI) to Health Protection Agency with fines for non-compliance; cleanyourhands campaign to be continued.
'Guide and training program of medical safety manger' was settled by MHLW – This document summarised the education programmes for medical safety mangers. It clarified the work for a medical safety manger [70].		DH issued Isolating patients with healthcare-associated infection: a summary of best practice [71].
'Measures to prevent in-hospital infection by drug-resistant bacteria and responses after occurrence'- MHLW – This document requests hospitals to change criteria of suspected an outbreak [72].		Improving cleanliness and infection control (Professional letter from Chief Nursing Officer/Director General of Finance). 5 key action areas in nursing (e.g. increasing the number of matrons to 5000 in acute NHS hospitals by May 2008, quarterly mandatory reporting on cleanliness and infection control by matrons and clinical directors to trust boards, etc.). [73]
JANIS Open Reports are available via internet since 2007 [14].		Deep clean campaign. The Secretary of State for Health announced Deep Clean initiative 'as part of the drive for a culture of cleanliness', an initial deep cleaning to have conducted by all NHS trusts before 31 March 2008. [66]
		DH issued The NHS in England: Operating Framework for NHS, 2008/2009 - locally agreed stretch targets alongside national targets for improving cleanliness and reducing MRSA & <i>C. difficile</i> were announced [74].
Japanese Society for Infection Prevention and Control started the Device-related infection surveillance [75].	2008	DH issued Clean, safe care: reducing infections and saving lives [76]. Promotion of innovations / new technologies and equipment was emphasised.
Board Certified Pharmacist in Infection Control, by the Japanese Society of Hospital Pharmacists.		Health and Social Care Act 2008 (c.14), required registration with the Care Quality Commission, and duty to protect patients against HCAs [77]. New code of practice.

Japan	Year	England
		MRSA screening operational guidance 2. Supplementary guidance to support trusts in introducing MRSA screening for all elective patients in March 2009.[78]
	2009	MRSA objective 2010/11 – relative to the median, with the best performers setting their objectives locally; embedding a culture of zero tolerance of preventable infections across any organisation (DH)[79].
Revision of medical reimbursement system: Hospital with ICT could receive additional fees (12 US\$ or £8.5) – MHLW [80].	2010	MRSA screening operational guidance 3 [81]. Supported NHS organisations in introducing MRSA screening for all relevant emergency admissions in December 2010.
MHLW issued the notification - About the establishment of ICT, the frequency and structure of ICT ward round, standards about outbreak [82].	2011	'Start Smart - Then Focus' launched - Guidance on antimicrobial stewardship in the secondary healthcare setting [83].
Revision of medical reimbursement system: Hospital with advanced infection control management could receive additional fees (12 to 48 US\$ or £8.5 - 34) – MHLW [84].	2012	Everyone counts: planning for patients 2013/14 [37]. Zero tolerance approach to MRSA bloodstream infections and mandatory Post Infection Review. Introduced on 1st April 2013.
Guideline for treatment of MRSA infection was published by the Japanese Association for Infectious Diseases/Japanese Society of Chemotherapy [85].	2013	The Chief Medical Officer's annual report on Infections and the rise of antimicrobial resistance [86].
		Locally set objectives for incidence of MRSA (& <i>C. difficile</i>) infection included in Quality Premium for CCGs, 12.5% (subject to the following achievements: no cases of MRSA bacteraemia assigned to the CCG). (In 2014/15, this was removed from Quality Premium). [87]
		DH issued UK Five year antimicrobial resistance strategy 2013 -2018 [4].
		Everyone counts: planning for patients 2014/15-2018/19 [88] - reiterates zero tolerance to MRSA (NHS England).
		NHS Standard Contract 2014/15 Particulars [89] issued in December 2013- National Quality Requirements for 2014/15 financial year – zero tolerance MRSA a national quality requirement (threshold 2014/15 is >0). Consequence of breach £10 000 in respect of each MRSA incidence in the relevant month (NHS England).
MHLW issued new definition of outbreak [47], [90].	2014	DH published Implementation of modified admission MRSA screening guidance for NHS [91]. Recommended 'a more focused, cost-effective approach to MRSA screening'.
		English Surveillance Programme for Antimicrobial Utilization and Resistance (ESPAUR), established by Public Health England. 1 st report published in September 2014 [92].
		Antibiotic Guardian Campaign, launched in association with European Antibiotic Awareness Day. Developed by various organisations, including Public Health England, and promotes everyone to pledge appropriate use of antibiotics.[93], [94]
MHLW issued recommendations on drug-resistant bacterial policy [95].	2015	National Risk Register of Civil Emergencies, 2015 edition, by Cabinet Office [96]. AMR was placed on the UK government risk register.
		Antibiotic Quality Premium (NHS England), aiming to improve antibiotic prescribing in primary and secondary care. CCGs rewarded for quality improvement, paid in the following financial year, and must be reinvested in quality or health outcome improvement.[97]
		DH issued The Health and Social Care Act 2008: Code of Practice on the prevention and control of infections and related guidance [39].
MHLW issued AMR National Action Plan [5].	2016	CQUIN Guidance for 2016/17, issued by NHS England [98]. AMR became one of 4 national indicators for CQUIN.
		AMR local indicators profile (including local surveillance data) on the 'Fingertips' data portal (publicly accessible interactive web tool and enhanced data visualisation), launched by Public Health England [99].
Guideline for treatment of MRSA infection, 2 nd edition was revised by The Japanese Association for Infectious Diseases/Japanese Society of Chemotherapy [100].	2017	

Abbreviations: AMR, antimicrobial resistance; BSIs, bloodstream infections; CCGs, Clinical Commissioning Groups; *C. difficile*, *Clostridium difficile*; CDI, *Clostridium difficile* infection; CQUIN, Commissioning for Quality and Innovation; DH,

Department of Health; DIPC, Director of Infection Prevention and Control; HCAs, healthcare-associated infections; ICT, infection control team; JANIS, Japan Nosocomial Infections Surveillance; MHLW, Ministry of Health, Labour and Welfare; MRSA, methicillin-resistant *Staphylococcus aureus*; NHS, National Health Service; UK, United Kingdom.

NB: CCGs are responsible for commissioning care for defined geographical populations (2013-).

ACCEPTED MANUSCRIPT

Table II

Comparison of the wider contextual factors and approaches to MRSA reduction / quality improvement between Japan and England (/UK)

Factor	Component	Japan	England (/UK)
SITUATIONAL	POLITICAL		
	Change of government & national leadership	<p>Political leadership instability:</p> <ul style="list-style-type: none"> • 15 terms of office (7 general election since 2000) of an average length of 1.9 years between July 1998 – December 2017 (range 0.8 -5.4 years). • September 2006 - December 2012: frequent leadership changes with 6 different prime ministers occurred, but only one prime minister since December 2012. • 10 coalition governments – <i>primarily</i> led by Liberal Democratic Party (LDP, <i>Jiminto</i> - Conservative), and shifted to Democratic Party of Japan (DPJ, <i>Minshuto</i> - Centrist), and then back to LDP. • The minister of Health, Labour and Welfare also changes frequently according to the governments. The current one was appointed at August 2017. 	<p>Wider political windows of opportunity for policy change:</p> <ul style="list-style-type: none"> • 8 terms of office of an average length of 4.1 years between May 1997 – December 2017 (range 1.2- 10.1 years). • 5 governments have been majority with 1 as coalition, shifting from Labour (Centre Left) with 2 different prime ministers to Conservative-Liberal Democratic, and to Conservative with 2 different prime ministers. • Secretary of State for Health was more stable under Coalition and Conservative governments rather than Labour governments (Centre Left & Left) in earlier periods, accounting for 1 and 4 turnovers respectively. The current one serving over 6 years (name changed to Secretary of State for Health and Social Care in January 2018).
	HEALTH		
	Life expectancy at birth (years)[106]	81 (2000) → 84 (2016)	78 (2000) → 81 (2016) [UK]
	Top five causes of death (age-standardised rate per 100 000 population by cause) between 2000 and 2016 [107]	<p>1) Stroke 50.5 (2000); 2) Ischaemic heart disease 43.8 (2000); 3) Lower respiratory infections 32.7 (2000); 4) Trachea, bronchus, lung cancer 21.9 (2000); 5) Stomach cancer 21.6 (2000)</p> <p>1) Ischaemic heart disease 31.5 (2016); 2) Stroke 25.8 (2016); 3) Lower respiratory infections 24.3 (2016); 4) Trachea, bronchus, lung cancer 19.6 (2016) 5) Self-harm 14.3 (2016)</p>	<p>1) Ischaemic heart disease 114.7 (2000); 2) Stroke 47.3 (2000); 3) Lower respiratory infections 46.0 (2000); 4) Trachea, bronchus, lung cancer 32.7 (2000) 5) Chronic obstructive pulmonary disease 26.9 (2000)</p> <p>1) Ischaemic heart disease 47.6 (2016); 2) Alzheimer disease and other dementias 37.6 (2016); 3) Trachea, bronchus, lung cancer 26.7 (2016); 4) Chronic obstructive pulmonary disease 23.1 (2016) 5) Stroke 21.6 (2016) [UK]</p>
	HEALTH CARE UTILISATION		
	Doctors consultations (in all settings) – Number per capita [108]	14.4 (2000) → 12.7 (2014)	5 (2009) [UK]
	Occupancy rate of curative (acute) care beds [109]	81.8% (2000) → 74.5% (2015)	83.4% (2001) → 84.3% (2010) [UK]
Average length of stay in hospital (days)[109]	24.8 (2000) → 16.5 (2015)	10.7 (2000) → 7.0 (2015) [UK]	
STRUCTURAL	POPULATION		
	Population structure by age group (% of total) [106]	<p>Aged 0-14: 15% (2000) → 14% (2008) → 13% (2016) Aged 15-64: 68% (2000) → 65% (2008) → 60% (2016) Aged 65 and above: 17% (2000) → 21% (2008) → 27% (2016) NB - Japan population, thousands: 127,534 (2000) → 127,749 (2016) [107].</p>	<p>Aged 0-14: 19% (2000) → 18% (2008) → 18% (2016) Aged 15-64: 65% (2000) → 66% (2008) → 64% (2016) Aged 65 and above: 16% (2000) → 16% (2008) → 18% (2016) NB - UK population, thousands: 58,951 (2000) → 65,789 (2016) [107].</p>

Factor	Component	Japan	England (/UK)
	Density of population (people per sq. km of land area) [106]	348 (2000) → 348 (2016)	243 (2000) → 271 (2016) [UK]
SOCIO-ECONOMIC			
	GDP per capita (current US\$, thousands)[106]	38.53 (2000) → 40.86 (2009) → 38.97 (2016)	27.98 (2000) → 38.26 (2009) → 40.41 (2016) [UK]
	Unemployment, total (% of total labour force)(modelled ILO estimate)[106]	4.7 (2000) → 5.1 (2009) → 2.8 (2017)	5.6 (2000) → 7.5 (2009) → 4.3 (2017) [UK]
	Poverty rate (% below poverty line of 60%) [110]	22%	18% [UK]
HEALTHCARE MODELS			
	Healthcare models [111]	Bismarck Model. Statutory health insurance system with a mixture of state regulation, social insurance financing, and private care provision [112]. The medical payment is calculated based on medical fee points. Patients pay part of this amount, and the public health insurance pays the remainder. The revision of the medical fee points is decided by the cabinet, the committee on health insurance, and the central social insurance medical council. These medical fee points are revised every two years.	Beveridge Model. NHS being publicly funded through taxation, and characterised by state regulation and control in the provision of services [112].
	Public system financing [113]	General tax revenue; insurance contributions.	General tax revenue (includes employment-related insurance contributions). [England]
	Provider ownership – hospitals [113]	Mainly private non-profit (~70% of beds), some public (~30%).	Mostly public, some private. [England]
	Hospital payment [113]	Case-based per diem payments and fee-for-service or fee-for-service only (includes physician costs).	Mainly case-based payments (60%) plus budgets for mental health, education, and research and training. All include physician costs, drug costs, etc. [England]
HEALTH EXPENDITURE			
	Total expenditure on health (% of GDP) (2016) [109]	Total: 10.9	Total: 9.7 [UK]
	Health expenditure by type of financing (2015) [109]	Government schemes: 9% Compulsory health insurance: 75% Out-of-pocket: 13% Voluntary health insurance: 2% Other: 1%	Government schemes: 80% Compulsory health insurance: 0% Out-of-pocket: 15% Voluntary health insurance: 3% Other: 2% [UK]
	Health expenditure by provider (2015)[109]	Hospitals: 41% Long-term care facilities:9% Ambulatory providers: 28% Retailers: 17% Other: 5%	Hospitals: 42% Long-term care facilities: 12% Ambulatory providers: 23% Retailers: 11% Other: 12% [UK]
HEALTH WORKFORCE			
	Practising doctors per 1000 pop.[109]	1.9 (2000) → 2.4 (2014)	2.0 (2000) → 2.8 (2015) [UK]

Factor	Component	Japan	England (/UK)
	Practising nurses per 1000 pop. [109]	8.4 (2002) → 11.0 (2014)	7.9 (2015) [UK]
	Ratio of nurses to doctors [109]	4.6 (2015)	2.8 (2015) [UK]
	Practising pharmacist per 100 000 pop. [109]	113 (2000) → 170 (2015)	59 (2002) → 83 (2015) [UK]
HEALTH INFRASTRUCTURE			
	Hospital beds per 1000 pop. [109]	14.7 (2000) → 13.2 (2015)	4.1 (2000) → 2.6 (2015) [UK]
Cultural	*National culture score (Hofstede country scores based on 6 dimensions)[114]	1) Power distance: 54 2) Individualism: 46 3) Masculinity: 95 4) Uncertainty avoidance: 92 5) Long-term orientation: 88 6) Indulgence: 42	1) Power distance: 35 2) Individualism: 89 3) Masculinity: 66 4) Uncertainty avoidance: 35 5) Long-term orientation: 51 6) Indulgence: 69 [UK]
Exogenous	Influence of international institutions	International alignment and influences apparent, especially US influence. e.g. 12% of interventions identified 2000-17, including MRSA related guidelines based on the Centers for Disease Control (CDC) guidelines and literature reviews, and regularly updated.	Nationally-based initiatives ahead of aspects of global initiatives.
Approaches to MRSA reduction / quality improvement	Requirement of surveillance	Voluntary: JANIS voluntary surveillance scheme since 2000 (but more comprehensively since 2007).	Mandatory: National MRSA mandatory surveillance since 2001. Zero tolerance approach to MRSA bloodstream infections and mandatory Post Infection Review (replacing previous root cause analysis) since April 2013.
	Mode of reporting / accountability	Closed information – confidential reporting: Hospital names are anonymised in JANIS open data sources, not intending to promote competitions between hospitals, but to encourage them to improve against their own historical performance trajectories (as bench-marking).	Open information – public reporting: Detailed information disclosure to the public done in an early period (e.g. public reporting of MRSA bloodstream infections at trust level began in 2002).
	Mode of motivation	Mainly intrinsic but with long-term objectives based largely on principles of <i>Kaizen</i> (continuous quality improvement).	Both extrinsic & intrinsic.
	Examples of incentive / sanction	Financial incentive: Many AMR interventions use financial incentives such as medical reimbursement system. Process-oriented sanction: Monetary sanctions were held at one time, and the sanctions targeted the infection control measure at hospitals. Process indicators considered as useful in Japan because immediate changes can be implemented.	Financial incentive: Commissioning for Quality and Innovation (CQUIN); quality premium. Outcomes-oriented sanction: Monetary sanctions were held for hospitals that cannot fulfil target reduction rates.

Abbreviations: AMR, antimicrobial resistance; GDP, Growth Domestic Product; JANIS, Japan Nosocomial Infections Surveillance; MRSA, methicillin-resistant *Staphylococcus aureus*; NHS, National Health Service.

NB: The UK comprises England, Scotland, Wales, and Northern Ireland. The data that are only available for the UK are specified in the table.

*1) Power distance: the degree to which the less powerful members of a society accept and expect that power is distributed unequally; 2) Individualism (versus Collectivism): preference for a loosely-knit social framework in which individuals are expected to take care of only themselves and their immediate families; 3) Masculinity (versus Femininity): a preference in society for achievement, heroism, assertiveness, and material rewards for success; 4) Uncertainty avoidance: the degree to which the members of a society feel uncomfortable with uncertainty and ambiguity; 5) Long-term orientation (versus short-term normative orientation): Long-term orientation takes a more pragmatic approach, encouraging thrift and efforts in modern education as a way to prepare for the future; 6) Indulgence (versus Restraint): Indulgence stands for a society that allows relatively free gratification of basic and natural human drives related to enjoying life and having fun. [115]

FIGURES

ACCEPTED MANUSCRIPT




Figure 1. Trends in rates of seven (multi)drug-resistant bacterial infections in Japan based on Antimicrobial-Resistant Bacterial Infection (ARBI) data (Average hospital participation rates ranged between 3% and 10% in 2007 and 2016 respectively); the 2007 data represent the average of July-December 2017 data) [15].

Abbreviations: MDRP, Multidrug-resistant *Pseudomonas aeruginosa*; PRSP, Penicillin-resistant *Streptococcus pneumoniae*. Note: Value of vancomycin-resistant *Staphylococcus aureus* (VRSA) indicates nil during the above period.




Figure 2. Trends in rates of MRSA, MSSA and *E. coli* bloodstream infections, and *C. difficile* infection (patients aged 2 years and over) for NHS acute trusts – All reported cases (England average)[8]–[12]

Abbreviations: MRSA, methicillin-resistant *Staphylococcus aureus*; BSI, blood stream infection; MSSA, methicillin-sensitive *S. aureus*; CDI, *Clostridium difficile* infection.

NB: 1) April 2001: Mandatory surveillance for MRSA BSIs; 2) January 2004: Mandatory surveillance of *C. difficile*-associated diarrhoea (CDAD) in patients aged 65 years and over began in NHS trusts; 3) April 2007: Mandatory surveillance of CDIs extended to all cases in patients aged 2 years and over for acute NHS trusts; 4) January 2011: Mandatory surveillance extended to methicillin-sensitive *S. aureus* BSIs; 5) June 2011: Mandatory surveillance extended to *Escherichia coli* BSIs.




Figure 3. Trends in MRSA and total number of relevant interventions: Japan (left) and England (right)

Abbreviations: MRSA, meticillin-resistant *Staphylococcus aureus*; BSI, bloodstream infection. Note: The 2007 MRSA infection data represent the average of July-December 2017 data.




Figure 4. Trends in MRSA and intervention type: Japan (left) and England (right)

Abbreviations: MRSA, methicillin-resistant *Staphylococcus aureus*; BSI, bloodstream infection. Note: The 2007 MRSA infection data represent the average of July-December 2017 data.

a: [campaign] Report of the Central Conference on Nosocomial Infection Control (September 2003).

b: [recommendation(g)] Infection control manual in elderly care welfare facility. Ministry of Health, Labour and Welfare, Japan (March 2013).

c: [mandatory] Infectious Disease Act (Prevention of Infectious Diseases and Medical Care for Patients with Infectious Diseases), revised. Ministry of Health, Labour and Welfare, Japan (November 2016).

d: [campaign] Clean~~your~~hands for hand hygiene improvement began, England and Wales (September 2004).

e: [mandatory] The Health Act 2006 (c.28) introduced requirement for provider registration with regulator, requirement for providers to ensure protection against HCAI, and (new) Code of Practice for the prevention and control of HCAs (July 2006).

f: [recommendation] National Institute for Health and Clinical Excellence (NICE) issued Surgical site infection: prevention and treatment of surgical site infection (CG74)(October 2008).




Figure 5. Trends in MRSA and the nature of relevant interventions: Japan (left) and England (right)

Abbreviations: MRSA, meticillin-resistant *Staphylococcus aureus*; BSI, bloodstream infection. Note: The 2007 MRSA infection data represent the average of July-December 2017 data.

g: [persuasive & structural] Japan Nosocomial Infections Surveillance (voluntary) began in 2000, but system change occurred in 2007 and consequently all surveillance data became available via internet (2007-).

h: [restrictive & persuasive] Implementing an Antibiotic Stewardship Programme, Guidelines by the American Society of Infectious Diseases and the American Medical Epidemiology Association (translated into Japanese)(May 2016).

i: [persuasive] Infection Control Manual for Pharmacists, 4th revision, Japanese Society of Hospital Pharmacists (April 2017).

j: [structural & restrictive] Introduction of mandatory surveillance for MRSA BSIs (April 2001).

k: [structural] Mandatory MRSA reporting changed from paper to a web-based system (January 2008).

l: [persuasive] Royal College of Nursing issued Wipe it out - one chance to get it right: Infection prevention and control - Information and learning resources for health care staff (January 2014)




Figure 6. Trends in MRSA and level of implementation of relevant interventions: Japan (left) and England (right)

Abbreviations: MRSA, meticillin-resistant *Staphylococcus aureus*; BSI, bloodstream infection. Note: The 2007 MRSA infection data represent the average of July-December 2017 data.

m: [macro, meso & micro] Infection Control Nursing Certified Nurse Specialist – Japanese Nursing Association. (Hospitals cannot obtain medical treatment compensation unless there is at least one nurse who has received appropriate education for infection control) (2006-).

n: [macro & meso] Measures to prevent in-hospital infection by drug-resistant bacteria and response after occurrence. Ministry of Health, Labour and Welfare, Japan (October 2007).

o: [meso] Guidelines for small and medium-sized hospitals and clinics and early identification of outbreaks. Ministry of Health, Labour and Welfare, Japan (2009).

p: [meso] National evidence-based guidelines for preventing healthcare-associated infections in NHS hospitals in England (epic1) published (January 2001).

q: [macro & meso] Everyone counts: planning for patients 2013/14 (December 2012) - Zero tolerance approach to MRSA BSIs and mandatory Post Infection Review mentioned. Required all NHS organisations (that report positive cases) to conduct a Post Infection Review from 1 April 2013.

r: [macro & micro] Health Education England issued, e-Learning e-LfH. Infection prevention and control modules: level 1 (2015).

LEGENDS:

Figure 1. Trends in rates of seven (multi)drug-resistant bacterial infections in Japan based on Antimicrobial-Resistant Bacterial Infection (ARBI) data (Average hospital participation rates ranged between 3% and 10% in 2007 and 2016 respectively); the 2007 data represent the average of July-December 2017 data) [15].

Abbreviations: MDRP, Multidrug-resistant *Pseudomonas aeruginosa*; PRSP, Penicillin-resistant *Streptococcus pneumoniae*. Note: Value of vancomycin-resistant *Staphylococcus aureus* (VRSA) indicates nil during the above period.




Figure 2. Trends in rates of MRSA, MSSA and *E. coli* bloodstream infections, and *C. difficile* infection (patients aged 2 years and over) for NHS acute trusts – All reported cases (England average)[8]–[12]

Abbreviations: MRSA, methicillin-resistant *Staphylococcus aureus*; BSI, blood stream infection; MSSA, methicillin-sensitive *S. aureus*; CDI, *Clostridium difficile* infection.

NB: 1) April 2001: Mandatory surveillance for MRSA BSIs; 2) January 2004: Mandatory surveillance of *C. difficile*-associated diarrhoea (CDAD) in patients aged 65 years and over began in NHS trusts; 3) April 2007: Mandatory surveillance of CDIs extended to all cases in patients aged 2 years and over for acute NHS trusts; 4) January 2011: Mandatory surveillance extended to methicillin-sensitive *S. aureus* BSIs; 5) June 2011: Mandatory surveillance extended to *Escherichia coli* BSIs.





Figure 3. Trends in MRSA and total number of relevant interventions: Japan (left) and England (right)

Abbreviations: MRSA, methicillin-resistant *Staphylococcus aureus*; BSI, bloodstream infection. Note: The 2007 MRSA infection data represent the average of July-December 2017 data.

Japan (left):



England (right):



Figure 4. Trends in MRSA and intervention type: Japan (left) and England (right)

Abbreviations: MRSA, methicillin-resistant *Staphylococcus aureus*; BSI, bloodstream infection. Note: The 2007 MRSA infection data represent the average of July-December 2017 data.

a: [campaign] Report of the Central Conference on Nosocomial Infection Control (September 2003).

b: [recommendation(g)] Infection control manual in elderly care welfare facility. Ministry of Health, Labour and Welfare, Japan (March 2013).

c: [mandatory] Infectious Disease Act (Prevention of Infectious Diseases and Medical Care for Patients with Infectious Diseases), revised. Ministry of Health, Labour and Welfare, Japan (November 2016).

d: [campaign] Clean~~your~~hands for hand hygiene improvement began, England and Wales (September 2004).

e: [mandatory] The Health Act 2006 (c.28) introduced requirement for provider registration with regulator, requirement for providers to ensure protection against HCAI, and (new) Code of Practice for the prevention and control of HCAIs (July 2006).

f: [recommendation] National Institute for Health and Clinical Excellence (NICE) issued Surgical site infection: prevention and treatment of surgical site infection (CG74)(October 2008).

Japan (left):


 Mandatory Recommendation Campaign MRSA infection

England (right):


 Mandatory Recommendation Campaign MRSA BSI

Figure 5. Trends in MRSA and nature of relevant interventions: Japan (left) and England (right)

Abbreviations: MRSA, methicillin-resistant *Staphylococcus aureus*; BSI, bloodstream infection. Note: The 2007 MRSA infection data represent the average of July-December 2017 data.

g: [persuasive & structural] Japan Nosocomial Infections Surveillance (voluntary) began in 2000, but system change occurred in 2007 and consequently all surveillance data became available via internet (2007-).

h: [restrictive & persuasive] Implementing an Antibiotic Stewardship Programme, Guidelines by the American Society of Infectious Diseases and the American Medical Epidemiology Association (translated into Japanese)(May 2016).

i: [persuasive] Infection Control Manual for Pharmacists, 4th revision, Japanese Society of Hospital Pharmacists (April 2017).

j: [structural & restrictive] Introduction of mandatory surveillance for MRSA BSIs (April 2001).

k: [structural] Mandatory MRSA reporting changed from paper to a web-based system (January 2008).

l: [persuasive] Royal College of Nursing issued Wipe it out - one chance to get it right: Infection prevention and control - Information and learning resources for health care staff (January 2014)

Japan (left):


 Restrictive Persuasive Structural MRSA infection

England (right):


 Restrictive Persuasive Structural MRSA BSI

Figure 6. Trends in MRSA and level of implementation of relevant interventions: Japan (left) and England (right)

Abbreviations: MRSA, methicillin-resistant *Staphylococcus aureus*; BSI, bloodstream infection. Note: The 2007 MRSA infection data represent the average of July-December 2017 data.

m: [macro, meso & micro] Infection Control Nursing Certified Nurse Specialist – Japanese Nursing Association. (Hospitals cannot obtain medical treatment compensation unless there is at least one nurse who has received appropriate education for infection control) (2006-).

n: [macro & meso] Measures to prevent in-hospital infection by drug-resistant bacteria and response after occurrence. Ministry of Health, Labour and Welfare, Japan (October 2007).

o: [meso] Guidelines for small and medium-sized hospitals and clinics and early identification of outbreaks. Ministry of Health, Labour and Welfare, Japan (2009).

p: [meso] National evidence-based guidelines for preventing healthcare-associated infections in NHS hospitals in England (epic1) published (January 2001).

q: [macro & meso] Everyone counts: planning for patients 2013/14 (December 2012) - Zero tolerance approach to MRSA BSIs and mandatory Post Infection Review mentioned. Required all NHS organisations (that report positive cases) to conduct a Post Infection Review from 1 April 2013.

r: [macro & micro] Health Education England issued, e-Learning e-LfH. Infection prevention and control modules: level 1 (2015).

Japan (left):

Macro Meso Micro MRSA infection

England (right):

Macro Meso Micro MRSA BSI